The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation: A randomized clinical study

Hepatology

Volumn 26, Issue 5, 1997, Pages 1143-1148

  García Huete, Lucía ^a,b   Domenech, Pere ^a   Sabaté, Antoni ^a   Martínez Brotons, Fernando ^a   Jaurrieta, Eduardo ^a   Figueras, Juan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; APROTININ; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; BLOOD SAMPLING; BLOOD TRANSFUSION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; INTRAOPERATIVE PERIOD; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030670450     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260509     Document Type: Article

References (48)

1. Maddrey WC, Van Thiel DH. Liver transplantation: an overview. HEPATOLOGY 1988;8:948.
2. Bismuth H, Ericzon BG, Rolles K, Castaing D, Otte JB, Ringe B, Sloof M. Hepatic transplantation in Europe. First report of the European liver transplant registry. Lancet 1987;19:674-676.
3. Mor E, Jennings L, Gonwa TA, Holman MJ, Gibbs J, Solomon H, Goldstein RM, et al. The impact of operative bleeding on outcome in transplantation of the liver. Surg Gynecol Obstet 1993;176:219-227.
4. Ritter CA, Owen CA, Bowie EJW, Rettke SR, Cole TL, Taswell HT. Evaluation of preoperative hematology-coagulation screening in liver transplantation. Mayo Clin Proc 1989;64:216-223.
5. Kang Y. Coagulation and liver transplantation. Transplant Proc 1993; 25:2001-2005.
6. Starzl TE, Iwatsuki S, Van Thiel DH, Gartner JC, Zitelli BJ, Malatack JJ, Schade RR, et al. Evolution of liver transplantation. HEPATOLOGY 1982;2:614-636.
7. Dzik WH, Arkin CF, Jenkins RL, Stump DC. Fribrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator. Blood 1988;71:1090-1095.
8. Grosse H, Lobbes W, Sato M, Ringe B, Barthels M. Systemic fibrinogenolysis in liver transplantation. Transplant Proc 1990;22:2303-2304.
9. Porte RJ. Coagulation and fibrinolysis in orthotopic liver transplantation: current views and insights. Semin Thromb Hemost 1993;19:191-196.
10. Kang Y. Clinical use of synthetic antifibrinolytic agents during liver transplantation. Semin Thromb Hemost 1993;19:258-261.
11. Kang Y, Lewis JH, Navalgund A, Russell MW, Bontempo FA, Niren LS, Starzl TE. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987;66:766-773.
12. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effects of aprotinin on need for blood transfusion after repeat open heart surgery. Lancet 1987;5:1289-1291.
13. Bidstrup BP, Royston D, Taylor KM, Cosgrove DM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364-372.
14. Royston D. High dose aprotinin therapy: a review of the first five years experience. J Cardiothor Vase Anest 1992;6:76-100.
15. Orchard MA, Goodchild S, Prentice RM, Davies JA, Benoit SE, Greighton-Kemsford LJ, Gaffney PJ, et al. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993;85:533-541.
16. Neuhaus P, Bechstein WO, Lefebre B, Blumhardt G, Slama KJ. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet 1989;14:924-925.
17. Mallett SV, Cox D, Burroughs AK, Rolles K. Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation. Lancet 1990;6:886-887.
18. Kang Y, De Wolf AM, Aggarwal S, Campbell E, Martin LK. In vitro study of the effects of aprotinin on coagulation during orthotopic liver transplantation. Transplant Proc 1991;23:1934-1935.
19. Grosse H, Lobbes W, Frambach M, von Broen O, Ringe B, Barthels M. The use of high dose aprotinin in liver transplantation: the influence on fibrinolysis and blood loss. Thromb Res 1991;63:287-297.
20. Mallett S, Rolles K, Cox D, Burroughs A, Hunt B. Intraoperative use of aprotinin (Trasylol) in orthotopic liver transplantation. Transplant Proc 1991;23:1931-1932.
21. Cottam S, Hunt B, Segal H, Ginsburg R, Potter D. Aprotinin inhibits tissue plasminogen activator-mediatec fibrinolysis during orthotopic liver transplantation. Transplant Proc 1991;23:1933.
22. Himmelreich G, Muser M, Neuhaus P, Bechstein WO, Slama KL, Jochum M, Riess H. Different aprotinin applications influencing hemostatic changes in orthotopic liver transplantation. Transplantation 1992; 53:132-136.
23. Groh J, Welte M, Azad SC, Forst H, Pratschke E, Kratzer MAA. Does aprotinin affect blood loss in liver transplantation [Letter]? Lancet 1992; 340:173.
24. Himmelreich G, Bechstein WO, Riess H. Aprotinin in liver transplantation. Biomed Prog 1993;6:40-43.
25. Van den Besselaar AMHP, Dirven R, Bertina RM. Tissue factor-induced coagulation can be inhibited by aprotinin (Trasylol). Thromb Haemost 1993;69:298-299.
26. Betchstein WO, Riess H, Neuhaus P, Himmelreich G, Steffen R, Slama KJ, Rossaint R, et al. The effect of aprotinin on blood product requirements during orthotopic liver transplantation. Clin Transplant 1991;5: 422-426.
27. Mallet SV, Cox D, Burroughs AK, Rolles K. The intra-operative use of aprotinin in liver transplantation. Transplant Int 1991;4:227-230.
28. Suarez M, Sangro B, Herrero JI, Picardi A, Páramo JA, Quiroga J, Pardo F, et al. Effectiveness of aprotinin in orthotopic liver transplantation. Semin Thromb Hemost 1993;19:292-96.
29. Himmelreich G, Kierzek B, Neuhaus P, Slama KJ, Riess H. Fibrinolytic changes and the influence of the early perfusate in orthotopic liver transplantation with intraoperative aprotinin treatment. Transplant Proc 1991;23:1936-1937.
30. Hunt BJ, Cottam S, Segal H, Ginsburg R, Potter D. Inhibition by aprotinin of t-PA-mediated fibrinolysis during orthotopic liver transplantation. Lancet 1990;336:381.
31. Lewis JH, Bontempo FA, Cornell FW, Kiss JE, Larson P, Ragni MV, Rice EO, et al. Blood use in liver transplantation. Transfusion 1987;27: 222-225.
32. Páramo JA, Rocha E. Hemostasis in advanced liver disease. Semin Thromb Hemost 1993;19:184-189.
33. Cohen H, Hunt B, Dixit M, Kanwar S, Thomas HC. Decreased contact factor mediated fibrinolysis in cirrhosis. Br J Haematol 1993;85:542-545.
34. Jovine E, Mazziotti A, Grazi GL, Ercolani G, Masetti M, Morganti M, et al. Piggy-back versus conventional technique in liver transplantation: report of a randomized trial. Transpl Int 1997;10:109-112.
35. Porte RJ, Bontempo FA, Knot EAR, Lewis JH, Kang YG, Starzl TE. Systemic effects on tissue plasminogen activator-associated fibrinolysis and its relation to thrombin formation in orthotopic liver transplantation. Transplantation 1989;47:978-985.
36. Groth CG, Pechet L, Starzl TE. Coagulation during and after orthotopic transplantation of the human liver. Arch Surg 1969;98:31-34.
37. Bakker CM, Metselaar HJ, Gomes MJ, Porte RJ, Groenland ThN, Schalm SW, Terpstra OT, et al. Intravascular coagulation in liver transplantation - is it present or not? Thromb Haemost 1993;69:25-28.
38. Himmelreich G, Rosch R, Neuhaus P, Riess H. Role of protein S in orthotopic liver transplantation. Semin Thromb Hemost 1993;19:286-289.
39. Otto G, Wolff H, Uerlings I, Gellert K. Preservation damage in liver transplantation. Influence of rapid cooling. Transplantation 1986;42: 122-124.
40. Riess H, Jochum M, Machleidt W, Himmelreich G, Bechstein WO, Muser M, Neuhaus P, et al. Role of leucocytes in hemostasis during orthotopic liver transplantation. Semin Thromb Hemost 1993;19:197-208.
41. Riewald M, Himmelreich G, Breindl P, Neuhaus P, Riess H. Soluble thrombomodulin levels during orthotopic liver transplantation. Semin Thromb Hemost 1993;19:246-249.
42. Palareti G, Legnani C, Mazziotti A, Zanello M, Sama C, Coccheri S. The "lytic state" during orthotopic liver transplantation: plasminogen activators and other protease activities. Semin Thromb Hemost 1993; 19:290-291.
43. Himmelreich G, Dooijewaard G, Neuhaus P, Kluft C, Bechstein WO, Riess H. Increased urokinase-type plasminogen activator (u-PA) levels in graft liver perfusate and decreased single chain u-PA activation with higher levels of aprotinin. Thromb Hemost 1994;71:12-14.
44. España F, Estelles A, Griffin JH, Aznar J, Gilabert J. Aprotinin (Trasylol) is a competitive inhibitor of activated Protein C. Thromb Res 1989;56: 751-756.
45. Segal HC, Hunt Bj, Cottam S, Beard C, Francis JL, Potter D, Tan KC. Changes in the contact system during orthotopic liver transplantation with and without aprotinin. Transplantation 1995;59:366-370.
46. Welte M, Groth J, Azad S, Anthuber M, Haller M, Kratzer M. Effect of aprotinin on coagulation parameters in liver transplantation. Semin Thromb Hemost 1993;19:297-299.
47. Lu H, Soria C, Commin PL, Piwnica A, Schumann F, Regnier O, Legrand Y, et al. Hemostasis in patients undergoing extracorporeal circulation: The effect of aprotinin (Trasylol). Thromb Haemost 1991;66:633-637.
48. Martínez-Brotóns F, Domenech P, Octavio C, Reynaldo C, Gallardo D, González-Barca E. Effects of aprotinin on hemostasis in patients undergoing cardiopulmonary bypass. Thromb Haemost 1993;69:1287.